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Introduction
IL-1 has been implicated as a pathogenic mediator in
numerous inflammatory and degenerative conditions,
including rheumatoid arthritis (RA) and osteoarthritis (OA)
[1]. The IL-1 receptor antagonist (IL-1Ra), a naturally
occurring inhibitor of the biologic actions of IL-1, has
obvious therapeutic potential in such diseases [2]; indeed
recombinant human IL-1Ra (anakinra) has recently been
approved for use in patients with RA as the drug KineretTM
(Amgen, Inc., Thousand Oaks, CA, USA).
Limitations of IL-1Ra as a pharmaceutical include its lack of
oral availability and its short biologic half-life. This is why in
clinical application KineretTM must be administered by daily
subcutaneous injection. Even then, it remains unlikely that a
therapeutic concentration of IL-1Ra will be maintained
between injections [3]; IL-1Ra is rapidly eliminated in the
kidney, resulting in a serum half-life of 4–6 hours following
intravenous injection into healthy, human volunteers. This
problem is exacerbated by the pronounced spare receptor
effect of IL-1. According to the literature [4–6] it is neces-
DMEM = Dulbecco’s modified Eagle medium; ELISA = enzyme-linked immunosorbent assay; FBS = fetal bovine serum; HSF = human synovial
fibroblast; (r/t)IL-1Ra = (recombinant/transgenic) IL-1 receptor antagonist; OA = osteoarthritis; PBS = phosphate-buffered saline; PGE2 =
prostaglandin E2; RA = rheumatoid arthritis.
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Abstract
Anakinra, the recombinant form of IL-1 receptor antagonist
(IL-1Ra), has been approved for clinical use in the treatment of
rheumatoid arthritis as the drug KineretTM, but it must be
administered daily by subcutaneous injection. Gene transfer
may offer a more effective means of delivery. In this study, using
prostaglandin E2 production as a measure of stimulation, we
quantitatively compared the ability of anakinra, as well as that of
IL-1Ra delivered by gene transfer, to inhibit the biologic actions
of IL-1β. Human synovial fibroblast cultures were incubated
with a range of doses of anakinra or HIG-82 cells genetically
modified to constitutively express IL-1Ra. The cultures were
then challenged with recombinant human IL-1β either
simultaneously with addition of the source of IL-1Ra or
24 hours later. In a similar manner, the potencies of the two
sources of IL-1Ra were compared when human synovial
fibroblasts were challenged with IL-1β produced constitutively
by genetically modified cells. No significant difference in
inhibitory activity was observed between recombinant protein
and IL-1Ra provided by the genetically modified cells, under
static culture conditions, even following incubation for 4 days.
However, under culture conditions that provided progressive
dilution of the culture media, striking differences between these
methods of protein delivery became readily apparent.
Constitutive synthesis of IL-1Ra by the genetically modified
cells provided sustained or increased protection from IL-1
stimulation over time, whereas the recombinant protein became
progressively less effective. This was particularly evident under
conditions of continuous IL-1β synthesis.
Keywords: arthritis, gene therapy, IL-1, IL-1 receptor antagonist, synoviocytes
Open Access
R301R302
Arthritis Research & Therapy    Vol 5 No 5 Gouze et al.
sary to maintain an IL-1Ra : IL-1 molar ratio of 10–100 or
more to achieve a strong inhibitory effect.
We have proposed IL-1Ra gene transfer as a means of
overcoming these problems [7]. The advantages of IL-1Ra
gene delivery include its ability to engender the continu-
ous production of therapeutic concentrations of IL-1Ra at
defined anatomic locations for extended periods of time –
potentially for life. Moreover, it is theoretically possible to
regulate levels of IL-1Ra gene expression in a manner
commensurate with disease activity [8]. IL-1Ra gene
therapy has been evaluated in a number of different animal
models of RA and OA, with extremely promising results
[9–18]. Indeed, a phase I human study of IL-1Ra gene
therapy in RA [19] was recently successfully completed.
During the preclinical development of IL-1Ra gene
therapy, we often noticed that transfer of the IL-1Ra gene
provided a far greater biologic effect than administration of
the recombinant protein. An example is provided by the
treatment of antigen-induced arthritis in rabbits. Lewth-
waite and coworkers [20] reported that repeated injection
of recombinant human IL-1Ra had no effect in this model
of RA beyond inhibition of the synovial fibrosis occurring in
the chronic stage of the disease. Otani and colleagues
[16], in contrast, observed a dramatic beneficial effect on
cartilage matrix metabolism, and a moderate anti-inflamma-
tory effect when administering IL-1Ra locally to joints via
ex vivo gene transfer.
There exist several possible explanations for the improved
effectiveness of IL-1Ra when delivered as a gene rather
than as a recombinant protein. The most likely of these are
as follows. First, gene transfer results in continuous, rather
than intermittent, protein delivery, thus maintaining a con-
stant supply of IL-1Ra at a concentration sufficient to
inhibit the biologic actions of IL-1. Second, gene delivery
produces a molecule that has been subjected to authentic
post-translational processing. Because the recombinant
molecule lacks glycosylation and has an extra amino-termi-
nal methionine, the native molecule may have greater bio-
logic potency than the recombinant one.
The present study was designed to compare quantitatively
the relative effectiveness of these two avenues of protein
delivery under controlled conditions in vitro. Cultures of
primary human synovial fibroblasts (HSFs) were treated
with human IL-1Ra, either administered as the recombi-
nant protein or by co-culture with fibroblasts genetically
engineered to express and secrete human IL-1Ra in a con-
stitutive manner. Stimulation from human IL-1β was then
provided by addition of recombinant IL-1β protein or by
co-culture with fibroblasts genetically engineered to con-
stitutively secrete high levels of human IL-1β [21]. Using
prostaglandin E2 (PGE2) levels in conditioned media as a
readout of IL-1 stimulation in the respective cultures, pro-
tection from IL-1 stimulation by each method was evalu-
ated under static and dynamic culture conditions, the
latter of which were designed to resemble more closely
the circumstance of an arthritic joint in which IL-1 is chron-
ically produced.
The data suggest that the recombinant and transgenic
molecules are similarly potent. Although the gene delivery
procedure may benefit marginally from increased concen-
tration at the cellular level, the advantage of gene transfer
as a means of drug delivery arises from the sustained
availability of IL-1Ra that this method permits.
Materials and method
Materials
Ham’s F12 medium, Dulbecco’s modified Eagle medium
(DMEM), fetal bovine serum (FBS), penicillin-streptomycin,
type II collagenase, dispase, and GeneticinTM were sup-
plied by Gibco-BRL (Rockville, MD, USA). ZeocinTM was
obtained from Invitrogen (Carlsbad, Ca, USA). Recombi-
nant human IL-1β and IL-1Ra were purchased from R&D
Systems (Minneapolis, MN, USA). ELISA kits for PGE2
and IL-1Ra were purchased from Dynatech (Ann Arbor,
MI, USA) and R&D Systems, respectively. ELISA kits for
human IL-1β were purchased from Endogen (Woburn,
MA, USA).
Reporter cell cultures
Human synovial tissues were recovered from joints of OA
patients undergoing total joint replacement surgery. HSFs
were isolated by sequential digestion of synovial fragments
with 1.5% dispase for 2 hours at 37°C and 0.2% collage-
nase for 2 hours. After washing in phosphate-buffered
saline the cells were cultured in 25cm2 dishes in DMEM
with 10% FBS and 1% penicillin-streptomycin. After the
third passage, the type B synovial cells were trypsinized,
counted, and cultured at a density of 5×105 cells per well
in 24-well plates with 1ml DMEM supplemented with 10%
FBS and 1% penicillin-streptomycin.
Engineered cell lines
To generate a cell line that provided a source of constitu-
tive production and secretion of transgenic IL-1Ra, the
rabbit synovial cell line HIG-82 [22] was cultured in 25cm2
flasks containing 4ml Ham’s F12 medium with 10% FBS
and 1% penicillin-streptomycin. Cells were grown to
approximately 75% confluence and incubated in the pres-
ence of 8µg/ml polybrene with 2ml supernatant containing
amphotropic retrovirus DFG-IRAP-zeor containing the
human IL-1Ra and Streptoalloteichus hindustanus
bleomycin-resistance (Sh ble; zeor) genes. The latter
allowed positive selection of the transduced cells in
medium containing Zeocin at 0.5 mg/ml. These cells,
HIG-82-IL-1Ra+, were found to secrete approximately 3µg
IL-1Ra/ml per 106 cells over 24 hours. The HIG-82 cells
were chosen for this purpose because they do not produceR303
PGE2 in response to IL-1β. Non-transduced HIG-82 cells
used as negative controls were cultured in Ham’s F12
medium with 10% FBS and 1% penicillin-streptomycin.
To generate cells that constitutively expressed human
IL-1β, skin was first harvested from a euthanized Wistar rat
(Charles River Laboratories, Wilmington, MA, USA),
minced with a scalpel, and digested for 2 hours at 37°C
under gentle agitation with 0.2% clostridial collagenase.
Dermal cells were recovered by centrifugation of the diges-
tion mixture at 5000rpm in a table top centrifuge, and then
cultured in 25cm2 flasks in DMEM with 10% FBS and 1%
penicillin-streptomycin. Adherent cells were transduced
with an amphotropic retrovirus, DFG-hIL-1β-neo, which
encodes the mature form of human IL-1β fused to the
leader sequence of human parathyroid hormone to enable
efficient secretion, and neomycin phosphotransferase [21].
Retroviral transductants were positively selected in com-
plete DMEM containing Geneticin at 0.5mg/ml. These
cells were found to secrete approximately 250ng human
IL-1β/ml per 106 cells over 24 hours.
IL-1 receptor antagonist and IL-1β β treatment
Human IL-1Ra or IL-1β was delivered as a recombinant
protein or by expression of its cDNA from genetically mod-
ified cells. For the addition of cells, cultures of HIG-82-
IL-1Ra+, or dermal fibroblasts secreting IL-1β, were
trypsinized, washed in PBS, and resuspended in complete
DMEM. The cells were then counted using a hemocytome-
ter and the appropriate number suspended in 50µl DMEM
for subsequent addition to the multiwell HSF cultures.
Biological assays
PGE2,  IL-1β, and IL-1Ra concentrations in conditioned
media were measured using ELISA according to the manu-
facturers’ instructions. These assays do not show any
cross-reactivity with other prostanoids, or rabbit and rat
forms of IL-1 or IL-1Ra. Under certain culture conditions,
such as those described in Figs 2–5, approximately 1/20,
or 50µl of the media volume was removed periodically and
replaced, in order to allow analysis at strategic time points
without significantly altering the evolving culture conditions.
Statistical analysis
All results are presented as means±SD. Statistical analy-
ses were performed using an unpaired Student’s t-test,
and P<0.05 was considered statistically significant.
Results
To quantitatively compare the ability of recombinant
(r)IL-1Ra and IL-1Ra provided by genetically modified cells
(i.e. transgenic [t]IL-1Ra) to inhibit the effects of IL-1β, we
performed a series of experiments using both static and
dynamic conditions of IL-1 stimulation. Because the syn-
ovium is an important contributor to pathogenesis in arthri-
tis, primary cultures of HSFs were used as target cells,
and concentrations of PGE2 in media conditioned by the
HSFs were used as a measure of IL-1β stimulation.
In our initial experiments we compared the inhibitory activity
of rIL-1Ra to that of HIG-82-IL-1Ra+ cells – a cell line engi-
neered to constitutively express human IL-1Ra – when
each was added to HSF cultures simultaneously with
IL-1β. For this, 5ng IL-1β was added to 5×105 HSFs
accompanied by either a range of doses of rIL-1Ra or
increasing numbers of HIG-82-IL-1Ra+ cells. Forty-eight
hours later, the conditioned media were analyzed for
IL-1Ra and PGE2 concentrations. A plot of IL-1Ra concen-
tration versus PGE2 production of the IL-1Ra treated cells,
relative to PGE2 levels of control HSFs incubated with
IL-1β alone, is shown in Fig.1. Over a wide range of doses
the recombinant and transgenic sources of IL-1Ra were
similarly capable of blocking the effects of the added IL-1β.
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Figure 1
Comparison of the relative inhibitory activity of recombinant IL-1Ra to
HIG-82-IL-1Ra+ cells when added to HSF cultures simultaneous to
stimulation with IL-1β. Approximately 5×105 HSFs were plated in
several wells of a 24-well plate. Twenty-four hours later, a range of
doses of rIL-1Ra (from 0.13 to 1µg) or HIG-82-IL-1Ra+ cells (ranging
from 4×102 to 4×105) was added to individual wells accompanied by
5ng recombinant IL-1β. Forty-eight hours later the conditioned media
were harvested and analyzed for IL-1Ra and PGE2 content by ELISA.
PGE2 levels were normalized to control, namely IL-1 stimulated HSF
cultures that did not receive IL-1Ra. PGE2 levels from these controls
were assigned a value of 100%. The relationship between the relative
PGE2 production and IL-1Ra concentration for each treatment group is
shown in the graph. The gray boxes represent the PGE2/IL-1Ra levels
for the rIL-1Ra treated cultures; white triangles represent those from
the cultures receiving the IL-1Ra producing cells. Experiments were
performed in triplicate, and each data point represents the mean
value±SD. ELISA = enzyme-linked immunosorbent assay; HSF,
human synovial fibroblast; IL-1Ra, IL-1 receptor antagonist; PGE2,
prostaglandin E2.For each source of IL-1Ra, 50% IL-1β inhibition was
extrapolated to a concentration of approximately 230ng/ml
IL-1Ra and complete inhibition at approximately 800ng/ml.
This translated to IL-1Ra:IL-1β ratios of approximately
46:1 and 160:1, respectively. In control experiments,
levels of PGE2 produced by IL-1β challenge of co-culture
of HSFs with nontransduced HIG-82 cells were found to
be identical to those of HSFs alone (data not shown).
Relative to the end-point concentrations of IL-1Ra, there
was no apparent difference in the effectiveness of the two
sources. By adding the recombinant protein and the modi-
fied cells at the same time as IL-1β, the concentration of
rIL-1Ra would be at its maximum at the time of initial IL-1β
stimulation. That of the tIL-1Ra, however, would be essen-
tially zero, and would not reach its maximal concentration
until 48 hours later, at the time of media harvest. Using this
rationale, we compared the effectiveness of rIL-1Ra and
tIL-1Ra under conditions in which the concentration of
each would be similar at the time of IL-1β stimulation. To
allow sufficient time for the IL-1Ra producing cells to
adhere and begin transgenic expression, we performed
experiments similar to that above, but added the IL-1β
24 hours after addition of the range of doses of rIL-1Ra or
tIL-1Ra producing cells to the HSF cultures. The condi-
tioned media were analyzed at the time of IL-1β addition
and 48 hours later for PGE2 and IL-1Ra content. A plot of
the IL-1Ra concentrations versus PGE2 production rela-
tive to IL-1β stimulated controls is shown in Fig.2. To illus-
trate the change in IL-1Ra concentration over time in the
wells receiving the IL-1Ra producing cells, we plotted the
final PGE2 concentration versus the IL-1Ra concentration
at the time of IL-1β stimulation and at the end of the
48 hour incubation. Because these values represent the
starting and end-point IL-1Ra concentrations, the effective
tIL-1Ra dose should lie somewhere between and is repre-
sented by the shaded area between the two curves.
As might be expected of a competitive inhibitor, preincu-
bation of the HSF with IL-1Ra for 24 hours before IL-1β
stimulation significantly reduced the 50% inhibition level
for each source of IL-1Ra. For the recombinant protein,
50% IL-1β inhibition was extrapolated to 50ng/ml IL-1Ra,
and for the tIL-1Ra 50% inhibition fell between 10 and
50ng/ml. For complete inhibition approximately 950ng/ml
rIL-Ra was required, whereas for the tIL-1Ra between 400
and 700ng/ml was necessary.
The previous experiments provided evidence that the two
molecules rIL-1Ra and tIL-1Ra were functionally similar
and equally capable of blocking the effects of IL-1β. They
also suggested that time was a factor critical to comparing
the effectiveness of rIL-1Ra and IL-1Ra constitutively pro-
duced by genetically modified cells. Thus, in several addi-
tional experiments we monitored the relationship between
IL-1Ra and IL-1β stimulation daily over a 96 hour interval.
For these experiments, three doses of rIL-1Ra or HIG-82-
IL-1Ra+ cells were used, which from Fig.2 provided either
low (approximately 10–15%), medium (approximately
25–50%), or high level (approximately 70–80%) inhibition
of IL-1β. HSFs were cultured in the presence of the various
doses of cells or protein, followed 24 hours later by the
addition of 5ng IL-1β. At 24 hour intervals, IL-1Ra and
PGE2 were measured in the conditioned media. As shown
in Fig.3, under these static culture conditions there was
little meaningful change in the levels of PGE2 production
over time. At the low and medium doses rIL-1Ra had little
protective effect but, relative to the 24 hour time point, a
significant increase in IL-1 stimulation was seen in the wells
receiving the high dose by day 4. In the wells receiving the
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Figure 2
Comparison of the relative inhibitory activity of HIG-82-IL-1Ra+ cells to
recombinant IL-1Ra when added to HSF cultures 24 hours before
stimulation with IL-1β. As in Fig.1, HSF were plated in multiwell plates
and incubated with a range of doses of rIL-1Ra or HIG-82-IL-1Ra+
cells. Twenty-four hours following the addition of the protein or cells,
5ng recombinant IL-1β was added, and the cultures were incubated
an additional 48 hours. PGE2 production at 48 hours after IL-1
stimulation for the IL-1Ra treated groups was normalized to control,
namely IL-1 stimulated HSF cultures that did not receive IL-1Ra.
Shown in the graph is the relationship between PGE2 production at
48 hours after IL-1 stimulation, and IL-1Ra concentration immediately
before and 48 hours after IL-1stimulation. PGE2/IL-1Ra levels for
cultures receiving the IL-1Ra producing cells are represented by
triangles; black indicates before IL-1 stimulation and white indicates
48 hours after. The shaded boxes represent the PGE2/IL-1Ra levels for
cultures receiving recombinant IL-1Ra. A single set of data points is
shown for the wells receiving the recombinant protein because the
IL-1Ra concentration did not change over time. The shaded region
between the curves is shown to emphasize the change in IL-1Ra levels
over time in the wells receiving the IL-1Ra producing cells.
Experiments were performed in triplicate, and each data point
repesents the mean value±SD. HSF, human synovial fibroblast; 
IL-1Ra, IL-1 receptor antagonist; PGE2, prostaglandin E2.HIG-82-IL-1Ra+ cells, protection from IL-1 stimulation was
maintained over time. Although the mean levels of PGE2
were reduced over the 4 days of the experiment, this was
not statistically significant. Thus, under these conditions
there were no dramatic differences between a single dose
of rIL-1Ra and the tIL-1Ra producing cells.
It has been shown in vivo that agents injected into the joint
space can be cleared from the synovial fluid in as little as
30 min, suggesting a steady egress of solutes from the joint.
Thus, to compare the effects of rIL-1Ra and tIL-1Ra produc-
ing cells under more dynamic conditions, perhaps closer to
those that might be encountered in the joint in vivo, experi-
ments were performed identically to that described for Fig.3
except that one half of the culture media was replaced every
24 hours for 4 days. Analysis of media recovered at each
day showed that the medium and low doses of rIL-1Ra pro-
vided a marginal level of protection over time, and in wells
receiving the highest dose initially high levels of protection
were steadily lost (Fig.4). In stark contrast, the HSFs incu-
bated with the IL-1Ra producing cells exhibited a sharp
reduction in PGE2 production throughout the course of the
experiment. For these groups, HSF cultures receiving even
the lowest dose of HIG-82-IL-1Ra+ cells showed approxi-
mately 70% inhibition of IL-1β at 96 hours.
The previous experiment was intended to evaluate the
effects of IL-1Ra under dynamic conditions following a
single stimulus of IL-1β. To establish a situation of chronic
IL-1β stimulation as might be encountered in an arthritic
joint, experiments were designed like that described for




Comparison of the relative inhibitory activity of HIG-82-IL-1Ra+ cells to recombinant IL-1Ra following extended incubation. HSF cultures were
incubated with one of three doses of rIL-1Ra (3, 30, or 300ng/ml) or IL-1Ra producing cells (3×103, 2×10 4, or 1×105) that secreted
corresponding levels of transgenic IL-1Ra protein within 24 hours. From the results of Fig.2 these doses provided either low (approximately
10–15%), medium (approximately 25–50%), or high level (approximately 70–80%) inhibition of IL-1β. Twenty-four hours following the addition of
the source of IL-1Ra, 5ng recombinant IL-1β was added to each culture well. At 24 hour intervals after IL-1 stimulation, PGE2 and IL-1Ra levels in
the conditioned media were measured. PGE2 levels were normalized to IL-1 stimulated HSF that were not treated with IL-1Ra, which were
assigned the value of 100%. The bottom graph represents the change in PGE2 levels in the media over time from cells receiving either rIL-1Ra or
the tIL-1Ra producing cells. The white bars represent cultures receiving the low dose of protein or cells, the grey bars the medium dose, and the
black bars the high dose. The inset above reflects the corresponding IL-1Ra concentrations in the conditioned media for each time point and dose.
Experiments were performed in triplicate, and each data point repesents the mean value±SD. *P<0.05 versus corresponding IL-1Ra source at
24 hours. HSF, human synovial fibroblast; IL-1Ra, IL-1 receptor antagonist; PGE2, prostaglandin E2.by the addition of dermal fibroblasts genetically modified
to constitutively secrete mature human IL-1β. As shown in
Fig.5, using these conditions the single dose of rIL-1Ra
was unable to block the effects of persistent IL-1β produc-
tion. Even at the highest dose, the steady dilution of
rIL-1Ra in the presence of constant IL-1β synthesis rapidly
lost its protective effects. In this milieu, however, the
potency of gene transfer as a method of drug delivery was
perhaps most effectively illustrated. The maintenance of
and gradual increase in IL-1Ra concentration provided by
ongoing synthesis by the genetically modified cells at all
doses provided sustained and increased protection from
chronic synthesis of IL-1β over time.
Discussion
For the treatment of arthritis, gene therapy has the theo-
retical advantage over protein therapy of sustained deliv-
ery of the therapeutic product to a discrete site.
Although its feasibility and effectiveness in animal
models are now well established [13,14,16–19,23–25],
no direct study of the intrinsic merits of using genetically
modified cells as a mechanism for protein delivery has
been reported. We postulated several potential benefits
that could arise, including natural protein processing and
intercellular presentation of the transgene product.
Indeed, it is known that anakinra, the recombinant form
of human IL-1Ra, differs from its naturally occurring
counterpart by possessing an additional amino-terminal
methionine residue and lacking glycosylation [26]. In the
first part of the present study similar end-point levels of
transgenic and recombinant IL-1Ra were necessary to
inhibit fully the response of synoviocytes to a single chal-
lenge with IL-1β. Furthermore, and in agreement with
earlier literature on this subject [4,5,27], both forms of
IL-1Ra required a molar excess over IL-1 of at least two
orders of magnitude to exercise an inhibition of 100%.
Altogether, these data suggest that the biochemical
alterations of the recombinant IL-1Ra do not significantly
affect its ability to antagonize the responses of synovial
fibroblasts to human IL-1β.
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Figure 4
Comparison of the relative inhibitory activity of HIG-82-IL-1Ra+ cells to recombinant IL-1Ra following periodic dilution. Experiments were performed
identically to those described for Fig.3, except that at 24 hour intervals after IL-1 stimulation one half of the conditioned media in each well was
removed and replaced with fresh media. As before, the PGE2 and IL-1Ra concentrations in the recovered media were measured using ELISA.
Experiments were performed in triplicate, and each data point repesents the mean value±SD. *P<0.05 versus corresponding IL-1Ra source at
24 hours. ELISA, enzyme-linked immunosorbent assay; IL-1Ra, IL-1 receptor antagonist; PGE2, prostaglandin E2.From the data presented in Fig.2, however, a modest
increase in the effectiveness of tIL-1Ra is suggested
when one considers the relative concentrations of
recombinant and transgenic IL-1Ra with time. In experi-
ments in which IL-1β was added at the same time as the
source of IL-1Ra, similar end-point concentrations of
IL-1Ra were found to provide corresponding inhibitory
effects, despite the fact that the recombinant protein
was at its maximal concentration at the time of IL-1 stim-
ulation whereas that from the modified cells was zero. In
other experiments in which, prior to IL-1 stimulation, time
was allowed for the IL-1Ra producing cells to establish
concentrations equivalent to that of the recombinant, the
inhibitory curve was shifted slightly to the left, indicating
a slight increase in the effectiveness of IL-1Ra when pro-
vided as a transgene product. This may arise from
increased concentrations of the IL-1Ra gene product in
the cellular microenvironment where the protein is locally
synthesized and secreted.
Interestingly, following extended culture under static con-
ditions, largely unremarkable differences in activity were
observed between the constitutively produced tIL-1Ra
and rIL-1Ra. Significant differences between the two
methods of protein delivery were only found under
dynamic conditions in which the concentration of rIL-1Ra
was reduced with time. In these situations, such as that
reported in Figs4 and 5, the importance of maintaining the
local level of IL-1Ra became dramatically apparent, as
were the advantages of gene transfer as a means of
protein delivery. In the face of continual dilution, the con-
stitutive production of the IL-1Ra gene product was able
to maintain effective protein levels and was able to sustain
and increase protection of the HSFs from IL-1 stimulation
as time progressed. This was even more pronounced
under conditions of continuing IL-1 production, in which
the rIL-1Ra was readily overwhelmed. It should be noted
that all of the experiments performed in this study used




Comparison of the relative inhibitory activity of HIG-82-IL-1Ra+ cells to recombinant IL-1Ra in the presence of chronic IL-1β stimulation.
Experiments were performed similar to those described for Fig.4, except that 2×104 rat dermal fibroblasts retrovirally transduced to constitutively
express and secrete human IL-1β were added to each culture well instead of recombinant IL-1β protein. PGE2 and IL-1Ra concentrations in the
conditioned media were measured at 24 hour intervals using ELISA. Experiments were performed in triplicate, and each data point repesents the
mean value±SD. *P<0.05 versus corresponding IL-1Ra source at 24 hours. ELISA, enzyme-linked immunosorbent assay; IL-1Ra, IL-1 receptor
antagonist; PGE2, prostaglandin E2.the amplitude of the responses to IL-1 and IL-1Ra may
vary somewhat between HSFs from OA, RA, and nondis-
eased individuals; however, the overall result will probably
remain the same.
In rodent models of RA, maximum therapeutic effects are
only achieved when pumps are used to maintain a con-
stant supply of large amounts of recombinant IL-1Ra.
Under these conditions IL-1Ra has both antierosive and
anti-inflammatory effects in collagen-induced arthritis. As
discussed by Bendele and coworkers [3], constant serum
concentrations of approximately 1µg IL-1Ra/ml are
antierosive, but it is necessary to achieve serum concen-
trations of approximately 5µg IL-1Ra/ml before important
anti-inflammatory effects are seen. A single, subcutaneous
injection of 150mg recombinant IL-1Ra in humans
achieves a peak plasma concentration of only about
1.6µg IL-1Ra/ml, and concentrations superior or equal to
1µg IL-1Ra/ml exist only for about 14 hours. Local, intra-
articular gene delivery of IL-1Ra could produce enough
protein, with only a single injection of vector, to trigger
both antierosive and anti-inflammatory local effects. This is
of real interest because the clinical response to Kineret is
modest and might be explained by these circumstances.
Moreover, its antierosive effect is more pronounced than
the anti-inflammatory one probably because of the low
local concentrations.
As suggested by our results, maintaining higher in vivo
concentrations of IL-1Ra in a sustained manner may be
key to realizing the full therapeutic potential of this mater-
ial. Gene delivery may offer the greatest chance of early
success. Recent data from our laboratory have shown that
the synovial lining is capable of maintaining therapeutic
levels of transgene expression for at least 6 months [28],
providing increased optimism for the use of gene transfer
in the treatment of chronic articular disease. Indeed,
IL-1Ra gene therapy has demonstrated impressive effi-
cacy in animal models of RA and OA, and a phase I human
trial has recently confirmed that the human IL-1Ra cDNA
can be safely transferred to and expressed within human
rheumatoid joints [19]. A planned phase II study will deter-
mine the efficacy of this procedure.
Conclusion
Recombinant human IL-1Ra and human IL-1Ra synthe-
sized transgenically in mammalian cells are equipotent
antagonists of human IL-1β. Our data indicate that the
greater efficiency noted for transgenic IL-1Ra in previous
animal gene therapy investigations reflects the ability of
gene delivery to maintain higher in vivo concentrations of
IL-1Ra in a sustained manner. This property was particu-
larly striking under experimental conditions that resemble
those found during chronic inflammatory conditions, in
which IL-1β is produced continually and the concentration
of rIL-1Ra administered as a single bolus progressively
falls. These findings are relevant to the clinical use of
Kineret and the possible future use of IL-1Ra gene therapy
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